These new agents will radically change our approach to the treatment of T2DM and obesity alike
In clinical trials of obese patients, tirzepatide showed even more impressive results in terms of weight loss from baseline, with an average reduction of 20-24%, and in some cases more than 30%, and became the first drug to outperform bariatric surgery (surgical procedures on the stomach and intestines aimed at treating obesity) in terms of effectiveness in studies
Patients who stick to their weekly schedule experience more predictable hunger patterns and better adherence to their nutrition goals compared to those who skip doses or inject irregularly
-30% Fat: Specifically targets stubborn visceral fat
By enhancing the performance of oral dosing choices as a replacement for disliked injections
It will be quite negative for our patients because data shows people typically regain weight after stopping the drugs, said Diana Thiara, medical director of the University of California-San Francisco Weight Management Program
